Divi's Laboratories Limited — Investor Meet, 15-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Divi's Laboratories reported a consolidated total income of ₹2,444 crore for the quarter, showing a significant increase from ₹1,995 crore year-over-year and ₹2,197 crore quarter-over-quarter. Profit before tax surged to ₹722 crore, up from ₹469 crore, while profit after tax reached ₹510 crore, compared to ₹348 crore in the previous year. The first half of FY25 also saw robust growth, with total income at ₹4,640 crore, up from ₹3,854 crore. The company's material consumption accounted for 41% of sales, and exports constituted about 87% of total revenue.

**Future Outlook and Growth Drivers:** Management expressed optimism regarding future growth, driven by a robust pipeline of generic products set to launch from 2026 and an increase in demand for their custom synthesis services. They highlighted ongoing investments to expand capabilities, particularly in Solid Phase Peptide Synthesis (SPPS), with anticipation of increased outputs and regulatory approvals contributing to future revenues.

**Order Book and Operational Updates:** The company noted a healthy order book, particularly in the Contrast Media segment, with several projects advancing toward commercial supply. With ongoing upgrades and expansions, especially at the new Unit-III facility expected to begin production in December, operational capabilities are set to improve.

**Analyst Q&A Insights:** Analysts raised concerns about pricing pressures in the generic drugs sector, with management confirming this is widespread rather than isolated to specific products. They acknowledged volume growth in key products despite challenges. Questions around capital expenditures revealed plans for ongoing significant investments, mainly focused on Greenfield projects, indicating strategic growth alignment with market demand.

**Market or Regulatory Updates:** The successful USFDA inspection at Unit-II reassured stakeholders of Divi's commitment to quality standards. Management emphasized proactive measures taken to navigate supply chain disruptions due to geopolitical factors.

**Strategic Focus Areas:** The company demonstrates a strategy of innovation and market adaptation, particularly in expanding green chemistry initiatives and enhancing production capacities in line with evolving market trends.

**Investor Insight:** With strong financial performance and a strategic focus on growth through product launches in generics and custom synthesis, Divi's Laboratories shows potential for a positive long-term outlook, which could justify a 'buy' position. The management's confidence in overcoming operational challenges and enhancing product offerings positions them favorably in the competitive landscape.